- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Real-World Data Shows Vorasidenib Could Address Earlier Treatment Needs in IDH-Mutant Glioma
November 29th 2025, 11:00am
Society for Neuro-Oncology Annual Meeting
Study findings indicate potential unmet needs for early vorasidenib treatment with minimal toxicity for patients with slow-growing IDH-mutant gliomas.
Vorasidenib Demonstrates Favorable Safety Profile and Disease Stability in High-Grade IDH-Mutant Gliomas
November 27th 2025, 2:00pm
Society for Neuro-Oncology Annual Meeting
Retrospective data showed vorasidenib displayed strong disease stability in addition to being well tolerated in grade 3 or 4 IDH-mutant glioma.,
Intraventricular B7-H3–Targeted CAR T-Cell Therapy Displays Safety in Recurrent Glioblastoma
November 25th 2025, 8:31pm
Society for Neuro-Oncology Annual Meeting
B7-H3–directed CAR T cell therapy was well-tolerated and demonstrated an acceptable safety profile in recurrent glioblastoma.
Vorasidenib Reduces Tumor Growth Rate in IDH1/2-Mutant Grade 2 Glioma
November 24th 2025, 9:03pm
Society for Neuro-Oncology Annual Meeting
INDIGO TGR analyses showed vorasidenib markedly slowed tumor growth and improved PFS and TTNI vs placebo in IDH1/2-mutant grade 2 glioma.
Dr Grommes on the Addition of Ibrutinib to R-MPV Induction in Newly Diagnosed PCNSL
November 24th 2025, 7:06pm
Society for Neuro-Oncology Annual Meeting
Christian Grommes, MD, shares results from a phase 2 study evaluating ibrutinib plus rituximab, methotrexate, vincristine, and procarbazine in PSNCL.
Dr Schaff on a Phase 1 Study of Copanlisib Plus Ibrutinib in Relapsed/Refractory PCNSL
November 24th 2025, 4:56pm
Society for Neuro-Oncology Annual Meeting
Lauren Shaff, MD, contextualizes results from a phase 1 study evaluating copanlisib plus ibrutinib in relapsed/refractory primary and secondary CNS lymphoma.
Dr Nayak on Findings From the PROSPECT Trial of Tirabrutinib in Relapsed/Refractory PCNSL
November 24th 2025, 4:48pm
Society for Neuro-Oncology Annual Meeting
Lakshmi Nayak, MD, discusses phase 2 efficacy and safety data with tirabrutinib in relapsed/refractory primary and secondary CNS lymphoma.
Sequential ICV/IV C7R-GD2 CAR T-Cell Therapy Is Better Tolerated in Pediatric CNS Tumors
November 24th 2025, 2:00pm
Society for Neuro-Oncology Annual Meeting
Sequential intracerebroventricular and intraventricular administration of CAR T-cell therapy was better tolerated in pediatric central nervous system tumors.
Vorasidenib Shows Rapid Real-World Uptake in IDH-Mutated Glioma
November 24th 2025, 1:00pm
Society for Neuro-Oncology Annual Meeting
Vorasidenib is being integrated in the real-world setting for the treatment of patients with IDH-mutated glioma.
18F-Fluciclovine Imaging Differentiates Progression From Treatment-Related Changes in Brain Metastases
November 23rd 2025, 11:20pm
Society for Neuro-Oncology Annual Meeting
18F-Fluciclovine PET/MRI detected disease progression and ruled out disease in non-progressors among patients with solid tumor brain metastases.
Lutetium Lu 177 Dotatate Shows Promise in Advanced Intracranial Meningioma
November 23rd 2025, 7:07pm
Society for Neuro-Oncology Annual Meeting
Phase 2 study finds 177Lu-Dotatate safe in advanced intracranial meningioma, with a 6-month PFS rate surpassing historical benchmarks.
Erdafitinib Is Safe and Shows Preliminary Efficacy in F3T3 Fusion+ Glioma
November 23rd 2025, 3:20am
Society for Neuro-Oncology Annual Meeting
Erdafitinib had a safety profile that was deemed tolerable in patients with recurrent or progressive IDH wild-type glioma harboring F3T3 gene fusions.
Eflornithine Plus Lomustine Extends PFS, OS in Reclassified WHO Grade 3 IDH-Mutated Astrocytoma
November 23rd 2025, 2:06am
Society for Neuro-Oncology Annual Meeting
Eflornithine plus lomustine produced superior OS and PFS outcomes vs lomustine in WHO grade 3 IDH-mutated astrocytoma.
Temozolomide Plus Radiotherapy Yields Survival Benefit in IDH-Mutant LGG
November 23rd 2025, 1:24am
Society for Neuro-Oncology Annual Meeting
Temozolomide plus radiotherapy significantly improved OS vs radiotherapy alone in IDH-mutant low-grade gliomas without codeletions of 1q and 19q.
Dr de la Fuente on Safety Data With Vorasidenib Plus Temozolomide in IDH-Mutant Glioma
November 23rd 2025, 12:52am
Society for Neuro-Oncology Annual Meeting
Macarena de la Fuente, MD, discusses safety data from the phase 1b IDHEAL-4U trial evaluating vorasidenib plus temozolomide in IDH-mutant glioma.
Dr Kurz on the Efficacy and Safety of Lutetium Lu 177 Dotatate in Advanced Intracranial Meningioma
November 22nd 2025, 10:15pm
Society for Neuro-Oncology Annual Meeting
Sylvia C. Kurz, MD, PhD, discusses the ongoing investigation of the SSTR2-targeting agent 177Lu-DOTATATE in advanced intracranial meningioma.
Mirdametinib Shows Improved ORR Over Time in NF1-Associated Symptomatic Plexiform Neurofibroma
November 22nd 2025, 9:05pm
Society for Neuro-Oncology Annual Meeting
Long-term ReNeu results showed deeper, more durable responses to mirdametinib in NF1-PN with extended treatment in both adults and children.
CAR T-Cell Therapy Shows Early Safety in Recurrent Brain/Leptomeningeal Mets From HER2+ Breast Cancer
November 22nd 2025, 8:18pm
Society for Neuro-Oncology Annual Meeting
HER2-directed CAR T-cell therapy was safe in patients with brain/leptomeningeal metastases from HER2-positive breast cancer.
Dr Lombardi on Phase 1 Data With Regorafenib Plus Temozolomide and CRT for Newly Diagnosed Glioblastoma
November 22nd 2025, 2:56pm
Society for Neuro-Oncology Annual Meeting
Giuseppe Lombardi, MD, PhD, discusses data with regorafenib plus temozolomide and radiation in newly diagnosed, MGMT-methylated, IDH-wild-type glioblastoma.
B7-H3–Directed CAR T-Cell Therapy Has Acceptable Safety Profile in Recurrent Glioblastoma
November 22nd 2025, 4:28am
Society for Neuro-Oncology Annual Meeting
B7-H3–directed CAR T-cell therapy given intraventricularly was well tolerated and showed early efficacy signals in patients with recurrent glioblastoma.